Drugs / 2-MERCAPTOETHANESULFONIC ACID
2-MERCAPTOETHANESULFONIC ACID
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | IFEX/MESNEX KIT | — | 1987-08-14 | fda.gov ↗ |
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04449536 | Nov 2020 → Oct 2021 | obesity disorder | University of Oslo | Completed | No outcome recorded |
| Phase 1 | NCT02660281 | Oct 2015 → Oct 2019 | immunodeficiency disease, myelofibrosis, plasma cell myeloma | University of Rochester | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00167219 | Nov 1999 → Jul 2022 | juvenile myelomonocytic leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1/2 | NCT00179816 | Apr 1999 → Sep 2012 | Ewing sarcoma, Hodgkins lymphoma, germ cell tumor, hepatoblastoma +1 | Ann & Robert H Lurie Children's Hospital of Chicago | Unknown | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT01333605 | Apr 2011 → Apr 2014 | Hodgkins lymphoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT01205503 | Sep 2010 → Aug 2012 | breast cancer, non-Hodgkin lymphoma | Mara Chambers | Completed | No outcome recorded |
| Phase 2 | NCT00774332 | Jun 2006 | acute lymphoblastic leukemia | Cooperative Study Group A for Hematology | Unknown | No outcome recorded |
| Phase 2 | NCT00126191 | Jul 2005 → Dec 2009 | Burkitt lymphoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00223548 | Oct 2002 → Dec 2004 | chronic renal failure syndrome | University of Ulm | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04486391 | Dec 2020 → Oct 2025 | classic Hodgkin lymphoma | BeiGene | Terminated | No outcome recorded |
| Phase 3 | NCT00002565 | May 1994 → Feb 2007 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01501149 | Jan 2011 → Dec 2015 | extranodal nasal NK/T cell lymphoma | Mingzhi Zhang | Unknown | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT05882604 | Mar 2023 → Mar 2024 | temporomandibular joint disorder | Tanta University | Completed | No outcome recorded |
| — | NCT05041686 | May 2019 → Feb 2021 | acute cholecystitis | AuXin Surgery SA | Completed | No outcome recorded |
| — | NCT01505569 | Oct 2011 → Feb 2024 | Ewing sarcoma, atypical teratoid rhabdoid tumor, germ cell tumor, hepatoblastoma +6 | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| — | NCT00758667 | Jan 2005 → Aug 2008 | breast disorder | Vanderbilt University | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 217 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 06 trials | ||||||
| Phase 0 | NCT06942039 Background | Sep 2025 → Dec 2030 expected | atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5 | C17 Council | Recruiting | No outcome recorded |
| Phase 0 | NCT05438667 Background | Jun 2023 → Jun 2028 expected | malignant pancreatic neoplasm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 0 | NCT04947501 Background | Jun 2021 → Jun 2026 overdue | childhood malignant neoplasm, neuroblastoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02212574 Background | Apr 2017 → Nov 2018 | medulloblastoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 0 | NCT01331590 Background | Jul 2011 → Oct 2014 | precursor lymphoblastic lymphoma/leukemia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT00515138 Background | May 2007 → Nov 2011 | B-cell non-Hodgkin lymphoma | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 136 trials | ||||||
| Phase 1 | NCT07257419 Background | Aug 2026 → Dec 2031 expected | childhood acute lymphoblastic leukemia, disease related to hematopoietic stem cell transplant | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06677710 Background | Jun → Dec 2026 | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Indapta Therapeutics, INC. | Suspended | No outcome recorded |
| Phase 1 | NCT07052370 Background | Sep 2025 → Dec 2028 expected | hematopoietic and lymphoid system neoplasm | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06777979 Background | Apr 2025 → Jan 2030 expected | B-cell acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06834282 Background | Apr 2025 → Dec 2026 expected | acute myeloid leukemia | CERo Therapeutics Holdings, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06190249 Background | Dec 2024 → Jan 2028 | melanoma | James Isaacs, MD | Withdrawn | No outcome recorded |
| Phase 1 | NCT06326463 Background | Oct 2024 → Jul 2030 expected | childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia, myelodysplastic syndrome | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05813327 Background | Mar 2024 → Apr 2026 overdue | soft tissue sarcoma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04881240 Background | Feb 2024 → Jul 2027 expected | childhood acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06027957 Background | Aug 2023 → Jun 2025 | B-cell acute lymphoblastic leukemia | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
| Phase 1 | NCT05581030 Background | May 2023 → Oct 2026 expected | acute lymphoblastic leukemia | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05298358 Background | Nov 2022 → Nov 2024 | systemic sclerosis | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1 | NCT05470283 Background | Sep 2022 → Apr 2027 expected | metastatic melanoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05170828 Background | Sep 2022 → Mar 2024 | T-lymphoblastic lymphoma, acute biphenotypic leukemia, acute undifferentiated leukemia, myelodysplastic syndrome | Ossium Health, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT04897321 Background | Jul 2022 → Mar 2027 expected | Ewing sarcoma, Wilms tumor, adrenal cortex carcinoma, childhood malignant neoplasm +10 | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT04653493 Background | Aug 2021 → Aug 2024 | B-cell acute lymphoblastic leukemia | Sabz Biomedicals | Unknown | No outcome recorded |
| Phase 1 | NCT04678401 Background | Jan 2021 → Aug 2028 expected | acute myeloid leukemia, graft versus host disease, myelodysplastic syndrome | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT04318678 Background | Jul 2020 → Jul 2029 expected | CD4+/CD56+ hematodermic neoplasm, T-cell acute lymphoblastic leukemia, acute myeloid leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT02167958 Background | Feb 2015 → Sep 2019 | leukemia, lymphoma, myelodysplastic syndrome, myelofibrosis | Rafic Farah, MD | Completed | No outcome recorded |
| Phase 1 | NCT01798004 Background | Apr 2013 → Jul 2015 | ganglioneuroblastoma, neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT01258634 Background | Jul 2010 → Nov 2011 | osteosarcoma, respiratory system cancer | University of Chicago | Terminated | No outcome recorded |
| Phase 1 | NCT00640796 Background | Sep 2008 → Apr 2014 | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma, acute myeloid leukemia, juvenile myelomonocytic leukemia +1 | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00742924 Background | Aug 2008 → Apr 2012 | sarcoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT00473551 Background | May 2007 → Nov 2009 | leukemia, plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00578266 Background | Feb 2007 → Aug 2016 | aplastic anemia | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00439361 Background | Feb 2007 → Jun 2012 | classic Hodgkin lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00278564 Background | Sep 2005 → Jul 2016 | myopathy | Northwestern University | Terminated | No outcome recorded |
| Phase 1 | NCT00623077 Background | Aug 2005 → Jul 2012 | central nervous system neoplasm, kidney cancer, liver cancer, retinoblastoma +1 | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 1 | NCT00091611 Background | Sep 2004 → Apr 2006 | kidney neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00278512 Background | Aug 2003 → Jun 2016 | vasculitis | Northwestern University | Terminated | No outcome recorded |
| Phase 1 | NCT00057005 Background | Feb 2003 → Oct 2009 | leukemia | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00424489 Background | Feb 2002 → Jun 2016 | myasthenia gravis | Northwestern University | Terminated | No outcome recorded |
| Phase 1 | NCT00058578 Background | Jun 1999 → Jun 2004 | systemic sclerosis | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00002740 Background | May 1996 → Mar 2004 | neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT00002854 Background | Dec 1994 → Aug 2015 | cancer | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00667927 Background | Mar 1991 → Jan 1995 | acute myeloid leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1/233 trials | ||||||
| Phase 1/2 | NCT07255664 Background | Nov 2025 → Apr 2027 expected | colorectal cancer, prostate cancer | CuraCell TX AB | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06119685 Background | Oct 2023 → Dec 2025 overdue | non-Hodgkin lymphoma, plasma cell myeloma | Indapta Therapeutics, INC. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06078696 Background | Sep 2023 → Dec 2024 | sickle cell disease | Columbia University | Terminated | No outcome recorded |
| Phase 1/2 | NCT05470491 Background | Jan 2023 → Jul 2026 overdue | HIV infectious disease, hematopoietic and lymphoid cell neoplasm | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05436418 Background | Nov 2022 → Jun 2027 expected | disease related to hematopoietic stem cell transplant | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05207722 Background | Apr 2022 → Feb 2024 | gastroesophageal junction adenocarcinoma | Celularity Incorporated | Terminated | No outcome recorded |
| Phase 1/2 | NCT05032183 Background | Feb 2022 → Jul 2024 | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04959175 Background | Sep 2021 → Apr 2027 expected | hematopoietic and lymphoid cell neoplasm | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03654040 Background | Apr 2021 → Mar 2023 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1/2 | NCT04752163 Background | Mar 2021 → Nov 2023 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04425070 Background | Aug 2020 → Dec 2025 | mature T-cell and NK-cell non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified | Antengene Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT04224558 Background | Nov 2019 → Sep 2027 expected | Crohn disease | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03577431 Background | Mar 2019 → Feb 2026 overdue | — | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03573700 Background | Jul 2018 → Jul 2023 overdue | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03056339 Background | Jun 2017 → Mar 2023 | B-cell chronic lymphocytic leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02356159 Background | Sep 2015 → Dec 2024 | Hodgkins lymphoma, acute leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02408042 Comparator | Apr → Nov 2015 | Hodgkins lymphoma, non-Hodgkin lymphoma | Western Regional Medical Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02282514 Background | Oct 2014 → Aug 2019 | classic stiff person syndrome | Northwestern University | Terminated | No outcome recorded |
| Phase 1/2 | NCT02053545 Background | Dec 2013 → May 2017 | leukemia, lymphoma, myelodysplastic syndrome | Ann & Robert H Lurie Children's Hospital of Chicago | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00692939 Background | Jun 2012 → Dec 2026 expected | Crohn disease | Paul Szabolcs | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01169636 Background | Jan 2011 → May 2017 | Hodgkins lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00968253 Background | Nov 2009 → Dec 2015 | acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00787722 Background | Oct 2009 → Nov 2018 | neuromyelitis optica | Northwestern University | Completed | No outcome recorded |
| Phase 1/2 | NCT00924287 Background | Nov 2008 → Dec 2010 | metastatic malignant neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00520130 Background | Oct 2007 → Oct 2015 | Hodgkins lymphoma, acute leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00541840 Background | Oct 2007 → Apr 2009 | soft tissue sarcoma | Spanish Group for Research in Sarcomas | Unknown | No outcome recorded |
| Phase 1/2 | NCT00429416 Background | Mar 2004 → Dec 2008 | hematopoietic and lymphoid cell neoplasm | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1/2 | NCT00048893 Background | Nov 2002 → Jun 2011 | breast cancer, metastatic malignant neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00093509 Background | Nov 1999 → Jul 2007 | sarcoma | Mark Dewhirst | Completed | No outcome recorded |
| Phase 1/2 | NCT00002627 Background | Nov 1994 → ? | breast cancer | St. Louis University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00002628 Background | Nov 1994 → ? | breast cancer | St. Louis University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00002510 Background | Apr 1992 → Jun 2001 | lymphoma | Temple University | Completed | No outcome recorded |
| Phase 1/2 | NCT00002509 Background | Nov 1991 → Dec 2003 | breast cancer | Temple University | Completed | No outcome recorded |
| Phase 2103 trials | ||||||
| Phase 2 | NCT07428993 Background | Jun 2026 → Dec 2034 expected | pediatric osteosarcoma | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06847269 Background | May 2025 → Mar 2030 expected | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06345495 Background | Oct 2024 → Jan 2027 expected | myelofibrosis, splenic disorder | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06593899 Background | May 2024 → Dec 2025 | soft tissue sarcoma | Fujian Medical University Union Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06001385 Background | Dec 2023 → Feb 2026 overdue | acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia, chronic myelomonocytic leukemia +3 | Center for International Blood and Marrow Transplant Research | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05579769 Background | Mar 2023 → May 2024 | myeloid neoplasm | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT05115630 Background | Apr 2022 → May 2025 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT04904588 Background | Sep 2021 → Aug 2026 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome | Center for International Blood and Marrow Transplant Research | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04684368 Background | Jul 2021 → Dec 2029 expected | choriocarcinoma, embryonal carcinoma, mixed germ cell tumor, pineal region immature teratoma +1 | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 2 | NCT04558736 Background | Jan 2021 → Jul 2029 expected | aplastic anemia, bone marrow failure syndrome | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04699214 Comparator | Sep 2020 → Aug 2023 | soft tissue sarcoma | Yong Chen | Unknown | No outcome recorded |
| Phase 2 | NCT04224337 Background | Jun 2020 → Aug 2023 | non-small cell lung carcinoma | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04187105 Background | Jan 2020 → Dec 2026 expected | acute leukemia, myelodysplastic syndrome | University of Illinois at Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT04154735 Background | Nov 2019 → Mar 2023 | Crohn disease | Northwestern University | Withdrawn | No outcome recorded |
| Phase 2 | NCT03849651 Background | Jan 2019 → Aug 2024 overdue | Hodgkins lymphoma, T-cell and NK-cell neoplasm, acute lymphoblastic leukemia, acute myeloid leukemia +3 | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03821610 Background | Nov 2018 → Oct 2025 overdue | acute lymphoblastic leukemia | University of Birmingham | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03663933 Background | Sep 2018 → Apr 2025 overdue | T-cell immunodeficiency, autoimmune lymphoproliferative syndrome, common variable immunodeficiency | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03630211 Background | Jul 2018 → Aug 2026 overdue | diffuse scleroderma, interstitial lung disease, pulmonary hypertension | Paul Szabolcs | Recruiting | No outcome recorded |
| Phase 2 | NCT03434704 Background | Jun 2018 → Oct 2019 | acute leukemia, fungal infectious disease, graft versus host disease, myelodysplastic syndrome | Ciceri Fabio | Completed | No outcome recorded |
| Phase 2 | NCT03263559 Background | Oct 2017 → Jan 2025 | sickle cell disease | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 2 | NCT03105596 Background | Apr 2017 → Sep 2018 | B-cell non-Hodgkin lymphoma | Peking University | Unknown | No outcome recorded |
| Phase 2 | NCT03651375 Background | Feb 2017 → Dec 2019 | dedifferentiated liposarcoma, fibrosarcoma, histiocytic sarcoma, leiomyosarcoma +8 | Maria Sklodowska-Curie National Research Institute of Oncology | Unknown | No outcome recorded |
| Phase 2 | NCT02793544 Comparator | Dec 2016 → Mar 2020 | B-cell chronic lymphocytic leukemia, acute biphenotypic leukemia, acute undifferentiated leukemia, myelodysplastic syndrome | Center for International Blood and Marrow Transplant Research | Completed | No outcome recorded |
| Phase 2 | NCT02732015 Background | Oct 2016 → Jul 2020 | sarcoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT02856997 Background | Sep 2016 → Mar 2019 | peripheral T-cell lymphoma, not otherwise specified | Yuankai Shi | Unknown | No outcome recorded |
| Phase 2 | NCT02790515 Background | Jul 2016 → Jul 2025 overdue | acute lymphoblastic leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome +1 | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02702960 Background | Mar 2016 → Jan 2018 | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded |
| Phase 2 | NCT02436707 Background | Oct 2015 → Jun 2026 overdue | lymphoma | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02106988 Background | Jan 2015 → Jan 2034 expected | lymphoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02133196 Background | Oct 2014 → Oct 2027 expected | adenocarcinoma, adenosquamous carcinoma, non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT02224872 Background | Aug 2014 → Dec 2021 | aplastic anemia, bone marrow failure syndrome | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT02199041 Background | Jul 2014 → May 2017 | hematopoietic and lymphoid cell neoplasm | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT02371161 Background | Feb 2014 → Dec 2018 | non-Hodgkin lymphoma | Fondazione Italiana Linfomi - ETS | Unknown | No outcome recorded |
| Phase 2 | NCT02029638 Background | Jan 2014 → Sep 2017 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT01857934 Background | Jul 2013 → Oct 2021 | neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01783535 Background | Jun 2013 → Mar 2023 overdue | retinoblastoma | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01854372 Background | Jun → Nov 2013 | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, diffuse large B-cell lymphoma | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded |
| Phase 2 | NCT01873326 Background | Jun 2013 → Jun 2027 expected | germ cell tumor | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01807611 Background | May 2013 → Aug 2021 | leukemia, lymphoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01864109 Background | May 2013 → May 2027 expected | Ewing sarcoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02676622 Background | Apr 2013 | Crohn disease | Nationwide Children's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT01319981 Background | Mar 2013 → Nov 2020 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01749072 Background | Dec 2012 → Dec 2016 | chemotherapy-induced toxicity, non-small cell lung carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01670084 Background | Dec 2012 → Sep 2015 | B-cell adult acute lymphocytic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 2 | NCT01453205 Background | Feb 2012 → Jul 2016 | diffuse large B-cell lymphoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT01481272 Background | Nov 2011 → Jul 2017 | diffuse large B-cell lymphoma | Polish Lymphoma Research Group | Completed | No outcome recorded |
| Phase 2 | NCT01329900 Background | Aug 2011 → Jul 2019 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01328496 Background | Jun 2011 → Oct 2016 | disease related to transplantation, hematopoietic and lymphoid cell neoplasm | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01181271 Background | Aug 2010 → Feb 2014 | Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma +1 | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01696669 Background | Mar 2010 → Dec 2017 | Ewing sarcoma | Spanish Group for Research in Sarcomas | Completed | No outcome recorded |
| Phase 2 | NCT01083342 Background | Jan 2010 → May 2012 | central nervous system non-hodgkin lymphoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01066429 Comparator | Dec 2009 → Dec 2010 | diffuse large B-cell lymphoma | Hospital Universitario Principe de Asturias | Unknown | No outcome recorded |
| Phase 2 | NCT01010217 Background | Nov 2009 → Oct 2017 | disease related to hematopoietic stem cell transplant, leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00958256 Background | Aug 2009 → Mar 2014 | mantle cell lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00941928 Background | Jul 2009 → May 2012 | childhood malignant neoplasm, leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00936936 Background | Jun 2009 → Jan 2024 | testicular cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00933673 Background | Jun 2009 → Jun 2012 | lymphoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT00823719 Background | May 2009 → Jul 2011 | diffuse large B-cell lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00878254 Background | Mar 2009 → Jun 2024 | mantle cell lymphoma | University of Miami | Completed | No outcome recorded |
| Phase 2 | NCT00857389 Background | Mar 2009 → Mar 2019 | disease related to hematopoietic stem cell transplant, leukemia, lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00801918 Background | Dec 2008 → Dec 2011 | anaplastic large cell lymphoma | Columbia University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00698009 Background | Jun 2008 → Jun 2012 | neuroblastoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00670748 Background | May 2008 → Jun 2016 | metastatic malignant neoplasm, metastatic melanoma, renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01102608 Background | Mar 2008 → Oct 2011 | soft tissue sarcoma | Spanish Group for Research in Sarcomas | Completed | No outcome recorded |
| Phase 2 | NCT00801580 Background | Mar 2008 → Sep 2010 | lymphoid leukemia | University of Bologna | Unknown | No outcome recorded |
| Phase 2 | NCT00636311 Background | Feb → Apr 2008 | Hodgkins lymphoma | Istituto Clinico Humanitas | Completed | No outcome recorded |
| Phase 2 | NCT00612222 Background | Jan 2008 → Mar 2011 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00504751 Background | May 2007 → Dec 2010 | non-Hodgkin lymphoma | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT00524199 Comparator | Mar → Jun 2007 | end stage renal failure | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 2 | NCT00568607 Background | Mar 2007 → Dec 2010 | lymphoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT00568464 Background | Mar 2007 → May 2009 | Ewing sarcoma | Fudan University | Terminated | No outcome recorded |
| Phase 2 | NCT00578864 Background | Mar 2007 → Jul 2009 | neuroblastoma | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00432094 Background | Dec 2006 → Mar 2021 | childhood germ cell tumor, ovarian carcinoma, teratoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00324467 Comparator | Aug 2006 → Dec 2021 | diffuse large B-cell lymphoma | British Columbia Cancer Agency | Unknown | No outcome recorded |
| Phase 2 | NCT00338377 Background | Feb 2006 → Feb 2030 expected | melanoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00189137 Background | Aug 2004 → Nov 2012 | soft tissue sarcoma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00450801 Background | Apr 2004 → Jul 2015 | lymphoma | University of Miami | Completed | No outcome recorded |
| Phase 2 | NCT00061893 Background | Apr 2004 → Apr 2008 | sarcoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00076752 Background | Jan 2004 → Oct 2013 | systemic lupus erythematosus | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00588094 Background | Oct 2003 → Mar 2010 | B-cell non-Hodgkin lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00290433 Background | Sep 2003 → Jul 2015 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00027846 Background | Aug 2003 → Jan 2010 | brain neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00067002 Background | Apr 2003 → Jul 2016 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00671658 Background | Nov 2002 → Jul 2013 | acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00580372 Background | Aug 2002 → Oct 2015 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 2 | NCT00038610 Background | Mar 2001 → Jul 2014 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00006373 Background | Feb 2000 → Oct 2006 | lymphoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00040482 Background | Apr 1999 → Aug 2005 | multiple sclerosis | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00002941 Background | Apr 1998 → Nov 2002 | lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00003042 Background | May 1997 → Feb 2010 | breast cancer | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00006260 Background | May 1997 → Jan 2005 | breast cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002791 Background | Feb 1997 → May 2002 | sarcoma | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00002804 Background | Sep 1996 → Jun 2000 | sarcoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00002785 Background | Jul 1996 → Aug 2000 | leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00002704 Background | Jan 1996 → Jun 2004 | leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00165139 Background | Jan 1996 → Nov 2000 | Ewing sarcoma, neuroblastoma, soft tissue sarcoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00002691 Background | Aug 1995 → Jun 2000 | lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002675 Background | May 1995 → Jan 2001 | intraocular retinoblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002865 Background | Apr 1995 → Jun 2000 | leukemia | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00004323 Background | Feb 1995 → ? | aplastic anemia | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 2 | NCT00002634 Background | Feb 1995 → Sep 2004 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002829 Background | Feb 1994 → Apr 2002 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002494 Background | May 1992 → Mar 2004 | leukemia, lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT06341998 Background | Jun 2020 → Jan 2024 | yolk sac tumor | Shandong First Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT03829566 Background | Nov 2019 → Jan 2025 | neuromyelitis optica | Northwestern University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03593902 Background | May 2018 → Oct 2019 | systemic sclerosis | Northwestern University | Terminated | No outcome recorded |
| Phase 2/3 | NCT00177047 Background | Apr 2004 → Aug 2020 | plasma cell myeloma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 317 trials | ||||||
| Phase 3 | NCT07187960 Comparator | Nov 2025 → Oct 2028 expected | follicular lymphoma | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04530565 Background | Jan 2021 → Jul 2028 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03342638 Background | Nov 2017 → Jul 2019 | relapsing-remitting multiple sclerosis | Northwestern University | Terminated | No outcome recorded |
| Phase 3 | NCT02810743 Comparator | Jan 2017 → Jul 2024 overdue | breast cancer | The Netherlands Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01445821 Background | Sep 2011 → Jan 2017 | systemic sclerosis | Northwestern University | Terminated | No outcome recorded |
| Phase 3 | NCT01096368 Background | May 2010 → Dec 2021 | anaplastic ependymoma, cellular ependymoma, clear cell ependymoma, papillary ependymoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00137995 Background | Jun 2003 → Oct 2008 | diffuse large B-cell lymphoma | Lymphoma Study Association | Completed | No outcome recorded |
| Phase 3 | NCT00658580 Background | Apr 2000 → Dec 2013 | small cell lung carcinoma | European Lung Cancer Working Party | Completed | No outcome recorded |
| Phase 3 | NCT00002875 Background | Dec 1996 → Feb 2006 | brain neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002816 Background | Dec 1996 → Nov 2002 | acute leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002784 Background | Jun 1996 → Aug 2011 | breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00002822 Background | Mar 1996 → Nov 2005 | small cell lung carcinoma | Medical Research Council | Completed | No outcome recorded |
| Phase 3 | NCT00002961 Comparator | Oct 1995 → Feb 2001 | leukemia | Children's Hospital of Philadelphia | Terminated | No outcome recorded |
| Phase 3 | NCT00002549 Background | Nov 1993 → ? | myeloid leukemia | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
| Phase 3 | NCT00002516 Background | Jul 1992 → ? | sarcoma | University Hospital Muenster | Unknown | No outcome recorded |
| Phase 3 | NCT00001300 Background | Jun 1992 → Mar 2001 | sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00002802 Background | Jul 1990 → Sep 2003 | neuroblastoma | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01731886 Comparator | Sep 2012 → Apr 2017 | plasma cell myeloma | Columbia University | Completed | No outcome recorded |
| Phase not applicable16 trials | ||||||
| — | NCT07389356 Background | Feb 2026 → Oct 2027 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| — | NCT05705687 Background | May 2023 → Feb 2031 expected | nongerminomatous germ cell tumor | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| — | NCT02880293 Background | Aug 2016 → Nov 2023 | hematopoietic and lymphoid cell neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT02652468 Background | Mar 2016 → Sep 2018 | lymphoma | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT01850108 Background | May 2013 → Nov 2023 | sickle cell disease | Vanderbilt-Ingram Cancer Center | Unknown | No outcome recorded |
| — | NCT01652092 Background | Sep 2012 → Dec 2025 overdue | Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, Omenn syndrome +6 | Masonic Cancer Center, University of Minnesota | Active not recruiting | No outcome recorded |
| — | NCT01490060 Background | May 2012 → Mar 2016 | chemotherapy-induced toxicity, sarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT01304849 Background | Jan 2011 → Sep 2013 | Hodgkins lymphoma | Cancer Institute WIA | Completed | No outcome recorded |
| — | NCT00673179 Background | May 2008 → Nov 2010 | osteosarcoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| — | NCT00578461 Background | Oct 2007 → May 2013 | Hodgkins lymphoma, cancer, leukemia, non-Hodgkin lymphoma | Baylor College of Medicine | Terminated | No outcome recorded |
| — | NCT00578539 Background | Oct 2007 → May 2013 | Hodgkins lymphoma, leukemia, myeloproliferative neoplasm, non-Hodgkin lymphoma | Baylor College of Medicine | Terminated | No outcome recorded |
| — | NCT00410488 Comparator | Dec 2006 → Jun 2011 | sarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT00578344 Background | Jul 2005 → Jul 2012 | sickle cell-hemoglobin c disease syndrome | Tami D. John | Terminated | No outcome recorded |
| — | NCT00066482 Background | Jul 2004 → Apr 2007 | childhood germ cell tumor, extragonadal germ cell tumor | Children's Oncology Group | Completed | No outcome recorded |
| — | NCT00578292 Background | Feb 2004 → May 2016 | thalassemia | Baylor College of Medicine | Terminated | No outcome recorded |
| — | NCT00042367 Background | Apr 2000 → Dec 2005 | brain cancer | Baylor College of Medicine | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00517894 Background | — | lymphoma | Study Group of Medical Tumour Therapy (AGMT) | No longer available | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 235 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-MERCAPTOETHANESULFONIC ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL1098319 ↗ |
| Known as | Coenzyme m sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1098319 ↗ |
| Known as | D 7093 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1098319 ↗ |
| Known as | Mercaptoethane Sulfonate | “Mesna Mercaptoethane Sulfonate, NSC-113891” NCT00002691 ↗3“Mesna Mercaptoethane sulfonate, NSC-113891” NCT00002549 ↗ “Mesna Mercaptoethane sulfonate, NSC-113891” NCT00002704 ↗ “Mesna Mercaptoethane sulfonate” NCT00002565 ↗ |
| Known as | MESNA | “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗230“Drugs:Chidamide and ICE regimen (ifosfamide, Mesna,Carboplatin and etoposide): Chidamide 20mg on d1,4,8,11;ifosfamide 1.2g/ m2，d1-4,ivg during 4 hours; Mesna 0.4g, 0,4,8 hours...” NCT02856997 ↗ “R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate...” NCT01854372 ↗ “Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between...” NCT03651375 ↗ “It is based on the property of the drug mesna (Sodium 2-mercaptoethane sulfonate) to cleave the disulfide bonds responsible for the adherence of pathological tissues and for...” NCT05041686 ↗ “Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA,...” NCT07187960 ↗ “Pretreatment with Mesna (Sodium 2-mercaptoethane sulfonate) in combination with sodium chloride is more protective than sodium chloride alone in animal models of acute renal failure.” NCT00223548 ↗ “MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.” NCT00578539 ↗ “AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W” NCT04699214 ↗ “* MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.” NCT01696669 ↗ “Mesna 500 mg/m2/day for NHL and 250 mg/m2/day for ALL, divided in three infusions: one day before the cyclophosphamide infusion, and 4 and 8 hours after.” NCT06027957 ↗ “Mesna 14.5 mg/kg IV starting 30 minutes prior to cyclophosphamide on Days -6 and -5 and continuing for at least 12 hours after end of cyclophosphamide” NCT04187105 ↗ “Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration” NCT00541840 ↗ “Mesna is also given orally with cyclophosphamide, to reduce the incidence of haemorrhagic cystitis, a common side effect of cyclophosphamide.” NCT05581030 ↗ “Mesna 500 mg/m2 IV at time-points 0, 3, 7 and 11 hours on the days when ifosfamide is administered (mesna could also be given orally)” NCT05705687 ↗ “intensified alkylating 'mini' CTC (2x) cyclophosphamide 3000 mg/m2 day 1 mesna 500 mg (push) + 2000 mg in 24 hours day 1 carboplatin” NCT02810743 ↗ “Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna.” NCT01328496 ↗ “L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w.” NCT00933673 ↗ “Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna)” NCT06593899 ↗ “Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.” NCT02133196 ↗ “The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna.” NCT00179816 ↗ “You will also receive mesna by vein over 30 minutes every 4 hours for a total of 10 mesna doses on Days 3 and 4.” NCT01010217 ↗ “Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes” NCT01205503 ↗ “ifosfamide + mesna - 5 grams (g)/meters squared (m\^2)/24 hours (hrs) continuous on day 2 of dosing cycle” NCT00823719 ↗ “DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w.” NCT00568607 ↗ “Clofarabine, Melphalan,Thiotepa, Cyclophosphamide, Mesna, Tacrolimus and mycophenolate mofetil (MMF)” NCT02053545 ↗ “3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks” NCT01102608 ↗ “Post-PBSC Infusion Conditioning: Mesna provided with Cytoxan according to institutional protocol.” NCT04224558 ↗ “Mesna: >80% of the cyclophosphamide dose in 3 divided doses from day +3 daily through day +5.” NCT03434704 ↗ “Mesna is a drug that protects bladder cells from damage by the chemotherapy drug ifosfamide.” NCT00439361 ↗ “Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna)” NCT00189137 ↗ “Additionally, mesna and sulfamethoxazole were prescribed to prevent hemorrhagic cystitis” NCT06341998 ↗ “Ifosfamide: 1.5g/m2 (with mesna) via IV infusion on day 2 to day 4 Q3W (up to 4cycles)” NCT04224337 ↗ “Mesna is a drug that lowers the risk of bladder side effects by the cyclophosphamide.” NCT00473551 ↗ “Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate.” NCT00517894 ↗ “Mesna is a drug that protects the bladder from damage by chemotherapy drugs.” NCT00958256 ↗ “Mesna: 1200 mg/m\^2 per day IV infusion, daily on days 6, -5, -4, and -3” NCT02356159 ↗ “Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3” NCT00520130 ↗ “With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide” NCT01304849 ↗ “Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine” NCT00774332 ↗ “0.4g Mesna injected at 0hour, 4hours and 8 hours after cyclophosphamide” NCT05438667 ↗ “ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3” NCT01453205 ↗ “Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4” NCT03105596 ↗ “VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)” NCT01083342 ↗ “Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours” NCT02676622 ↗ “Cyclophosphamide, Fludarabine, Interleukin-2, Mesna” NCT00640796 ↗ “Mesna 50 mg/kg IV concomitant with cyclophosphamide” NCT05470491 ↗ “Mesna 6 mg/kg IV in 0.65 ml/kg of IVF over 15 min” NCT00042367 ↗ “mesna 5 g/m2 synchronously iv infusion for rescue” NCT04425070 ↗ “Ifosfamide with Mesna equidone 5000 mg/mq, day 2” NCT02371161 ↗ “the efficacy of the drug Mesna® (Uromitexan)” NCT04449536 ↗ “Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA)” NCT00636311 ↗ “Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1” NCT00580372 ↗ “with Mesna 15 mg/kg day x 2 days over 1 hour” NCT00612222 ↗ “with Mesna 15 mg/kg/day X 2 days over 1 hr.” NCT00670748 ↗ “MESNA (If the dose of Cyclophosphamide” NCT01066429 ↗ “ifosfamide with mesna, each 5 mg/m(2)” NCT00515138 ↗ “Mesna (200mg/m2/dose) Day 1 and 2.” NCT00027846 ↗ “Mesna 400 mg 0,4,8h at days 1-4” NCT01333605 ↗ “6 5 CYTOXAN 50 mg/kg WITH MESNA” NCT00578266 ↗ “Mesna- 10 mg/kg/ IV Day 3, 4” NCT05298358 ↗ “Mesna 3000 mg/m2/d X 3 days” NCT00801918 ↗ “Mesna 240 mg/m2 tid d1” NCT00568464 ↗ “* Mesna * Methotrexate” NCT00801580 ↗ “Drug: Mesna” NCT00787722 ↗ “Drug: Mesna” NCT05170828 ↗ “Drug: Mesna” NCT00936936 ↗ “* Mesna” NCT00167219 ↗ “Mesna” NCT00048893 ↗ |
| Known as | Mesna - sodium 2-mercapto-ethanesulphonate | “Mesna - sodium 2-mercapto-ethanesulphonate” NCT00093509 ↗ |
| Known as | mesna: Mesnex(R) | “mesna: Mesnex(R)” NCT00640796 ↗ |
| Known as | Mesnex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1098319 ↗ |
| Known as | Mistabron | ChEMBL registry synonym — accepted as the source's own label CHEMBL1098319 ↗ |
| Known as | NSC-113891 | “Mesna Mercaptoethane sulfonate, NSC-113891” NCT00002704 ↗3“Mesna Mercaptoethane Sulfonate, NSC-113891” NCT00002691 ↗ “and Mesna, NSC-113891.” NCT00001300 ↗ “Mesna, NSC-113891” NCT00002510 ↗ |
| Known as | Sodium 2-mercaptoethane sulfonate | “This study evaluated sodium-2-mercaptoethane sulfonate (Mesna) co-administration with doxorubicin to reduce doxorubicin-induced plasma protein oxidation and resultant cascade...” PMID 25909710 ↗ Apr 20152“MESNA (sodium 2-mercaptoethanesulfonate) was approved several years ago and marketed in several formulations as a mucolytic agent in the respiratory field, since it breaks the...” NCT05882604 ↗ “It is based on the property of the drug mesna (Sodium 2-mercaptoethane sulfonate) to cleave the disulfide bonds responsible for the adherence of pathological tissues and for...” NCT05041686 ↗ |
| Known as | Uromitexan | “Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks” NCT00658580 ↗ |
| Modality | Small molecule | “Mesna is a synthetic sulfhydryl (thiol) compound.” NCT03849651 ↗ |
| Route | Intravenous | “Given IV” NCT00002816 ↗ |